Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study.
Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study.
复制标题
DOI：
10.3390/jcm9113406
复制
发表时间：
2020-10-23
影响因子：
3.9
通讯作者：
Kim WY
中科院分区：
文献类型：
--
作者：
Choi JC;Jung SY;Yoon UA;You SH;Kim MS;Baek MS;Jung JW;Kim WY
吸入皮质类固醇 (ICS) 可能会增加 2019 年冠状病毒病 (COVID-19) 的风险并导致不良后果。为了比较 ICS 用户和非用户之间的临床结果，对韩国健康保险审查和评估数据库中与 COVID-19 相关的索赔进行了评估。为了评估 COPD 或哮喘患者对 COVID-19 的易感性，使用同一数据库进行了一项巢式病例对照研究。总共有 7341 名患者被确认患有 COVID-19，其中包括 114 名 ICS 用户和 7227 名非用户。在 5910 名住院患者中，ICS 用户中有 9% 死亡，非用户中有 4% 死亡。然而，在调整年龄、性别、地区、合并症和医院类型后，这种相关性并不显着（aOR，0.94；95% CI，0.43-2.07）。 COPD 病例对照分析将 640 例 COVID-19 病例与 2560 例无 COVID-19 的匹配对照进行比较，哮喘分析将 90 例 COVID-19 病例与 360 例无 COVID-19 的匹配对照进行比较。在 COPD（aOR，1.02；95% CI，0.46-2.25）或哮喘（aOR，0.38；95% CI，0.13-1.17）患者中，ICS 的使用与 COVID-19 没有显着相关性。既往使用 ICS 与 COPD 或哮喘患者的 COVID-19 没有显着相关性，也与 COVID-19 患者的临床结果显着相关。
Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility to COVID-19 among patients with COPD or asthma, a nested case-control study was performed using the same database. In total, 7341 patients were confirmed to have COVID-19, including 114 ICS users and 7227 nonusers. Among 5910 patients who were hospitalized, death was observed for 9% of ICS users and 4% of nonusers. However, this association was not significant when adjusted for age, sex, region, comorbidities, and hospital type (aOR, 0.94; 95% CI, 0.43–2.07). The case-control analysis of COPD compared 640 cases with COVID-19 to 2560 matched controls without COVID-19, and the analysis of asthma compared 90 cases with COVID-19 to 360 matched controls without COVID-19. Use of ICS was not significantly associated with COVID-19 among patients with COPD (aOR, 1.02; 95% CI, 0.46–2.25) or asthma (aOR, 0.38; 95% CI, 0.13–1.17). Prior ICS use was not significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among patients with COVID-19.
登录
查看更多内容
DOI：
10.1164/rccm.202002-0445oc
发表时间：
2020-06-01
影响因子：
24.7
作者：
Feng, Yun;Ling, Yun;Qu, Jieming
通讯作者：
Qu, Jieming
影响因子：
7.6
作者：
Rosenberg, Helene F.;Dyer, Kimberly D.;Domachowske, Joseph B.
通讯作者：
Domachowske, Joseph B.
影响因子：
9.1
作者：
Liu S;Zhi Y;Ying S
通讯作者：
Ying S
DOI：
10.1164/rccm.202003-0821oc
发表时间：
2020-07-01
影响因子：
24.7
作者：
Peters, Michael C.;Sajuthi, Satria;Fahy, John, V
通讯作者：
Fahy, John, V
影响因子：
15.8
作者：
Stockman LJ;Bellamy R;Garner P
通讯作者：
Garner P